

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**(1) PROPOSED APPOINTMENT OF SUPERVISOR;
(2) PROPOSED CHANGE OF REGISTERED ADDRESS;
AND
(3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION**

(1) PROPOSED APPOINTMENT OF SUPERVISOR

As disclosed in the announcement of the Company dated October 31, 2025, Mr. Yang Ming has resigned from his position as a supervisor of the Company due to retirement. The Board proposed to appoint Ms. Fan Xinyu (“**Ms. Fan**”) as a supervisor. Her term of office, if approved by the Shareholders at the AGM, will commence from the date on which the relevant resolution is passed at the AGM until the expiration of the term of the second session of the Board, subject to re-election upon the expiry of her term of office.

Details of the biography of Ms. Fan are set out as follows:

Ms. Fan Xinyu (範馨予) (“**Ms. Fan**”), aged 51, is a Supervisor of the Company. Ms. Fan joined Lepu Medical in March 2005 and served in various positions until June 2013, including the manager of public relations department, marketing department and general office, as well as the director of key accounts department. From July 2013 to April 2019, Ms. Fan served at Beijing Fert Technology Co., Ltd. (北京伏爾特技術有限公司), where she successively held the positions of Beijing regional sales director, marketing director and administrative director. Ms. Fan rejoined Lepu Medical in May 2019 and successively served as the director of key accounts department, the deputy director of organization and human resources center and director of the Cadre Management division I.

Ms. Fan obtained a master's degree in industrial economics from Capital University of Economics and Business (首都經濟貿易大學) in the PRC in January 2003.

As at the Latest Practicable Date, Ms. Fan has not entered into service contract with the Company in respect of her appointment as a supervisor of the Company. The appointment of Ms. Fan as a supervisor of the Company will be effective upon the approval of the Shareholders at the AGM and end on the expiration of the term of the second session of the Supervisory Committee, subject to re-election upon the expiry of her term of office.

Ms. Fan has confirmed that she (i) has not held any other position within the Company and its subsidiaries and has not held any directorships in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations required to be disclosed pursuant to Part XV of the SFO; and (iii) save for the information disclosed above, has no relationships with any other Directors, Supervisors, members of senior management or substantial Shareholders. Save as disclosed herein, there is no other information required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

Subject to the approval of the Shareholders by way of an ordinary resolution at the AGM, the Company will enter into a service contract with Ms. Fan. Ms. Fan will receive an annual remuneration of RMB150,000 from the Company during her term as a supervisor of the Company.

(2) PROPOSED CHANGE OF REGISTERED ADDRESS

The Company proposes to change its registered address from “Room C280, Building 1, No. 1628 Su Zhao Road, Minhang District, Shanghai” to “Block 4, No. 651, Lianheng Road, Minhang District, Shanghai, the PRC”. The change in registered address is subject to review and approval by the industrial and commercial registration authorities.

(3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION

In view of the above proposed change of registered address, the Board proposes to make corresponding amendments to the Articles of Association.

Details of the proposed amendments to the Articles of Association are set out below:

No.	Original Article		Amended Article	
1	Article 4	Chinese name of the Company: 樂普生物科技股份有限公司 English name of the Company: Lepu Biopharma Co., Ltd. Address of the Company: Room C280, Building 1, No. 1628 Su Zhao Road, Minhang District, Shanghai Postal code: 201114 Telephone No.: (86) 021-67696099 Fax No.: (86) 021-67696770	Article 4	Chinese name of the Company: 樂普生物科技股份有限公司 English name of the Company: Lepu Biopharma Co., Ltd. Address of the Company: Block 4, No. 651, Lianheng Road, Minhang District, Shanghai, the PRC Postal code: 201114 Telephone No.: (86) 021-67696099 Fax No.: (86) 021-67696770

Save for the proposed amendments set out above, other provisions in the Articles of Association remain unchanged.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“AGM” or “Annual General Meeting”	the 2025 annual general meeting of the Company to be held on May 19, 2026
“Articles of Association”	the articles of association of the Company, as amended from time to time
“Board” or “Board of Directors”	the board of Directors of the Company
“Company” or “Lepu Biopharma”	Lepu Biopharma Co., Ltd. (樂普生物科技股份有限公司), a company incorporated in the PRC with limited liability, the H Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2157)
“Director(s)”	the director(s) of the Company from time to time
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
“PRC”	the People’s Republic of China, for the purpose of this announcement, excluding the regions of Hong Kong, Macao Special Administrative Region of the People’s Republic of China and Taiwan
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisors”	the supervisor(s) of the Company from time to time
“Supervisory Committee”	the supervisory committee of the Company

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
April 27, 2026

As at the date of this notice, the Board comprises Dr. Pu Zhongjie (Chairman) and Dr. Sui Ziyue (Chief Executive Officer) as executive Directors; Ms. Pu Jue and Ms. Qin Yiran as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.